Enuresis, Polyuria
Conditions
Keywords
MNE with nocturnal polyuria, monosymptomatic nocturnal enuresis with nocturnal polyuria
Brief summary
Alarm-treatment as well as Desmopressin, a synthetic analogue of human vasopressin, are considered the only evidence-based medicine (EBM) IA treatments in monosymptomatic nocturnal enuresis (MNE). Desmopressin exists in three different formulations for ambulant use: nasal spray, tablet and lyophilisate (MELT) each with differences in bioavailability (spray 2%, tablet 0.2%, MELT 0.5%). There 's insufficient evidence to confirm the actually used bioequivalent doses ( 10µg spray = 120µg MELT= 0.2mg tablet). Although so frequently used, very few pharmacokinetic and -dynamic data on desmopressin are available for children. Due to prolonged half life, associated with waterintoxication,the nasal spray has a black box warning from the FDA and is no longer recommended . For some authors oral formulations appear to be a safer alternative. However, based on clinical experience of less response rate with oral formulations, lower biodisponibility is suspected. Adult research confirms low bioavailability of tablets but also show major influences by food-intake and changes in gastro-intestinal motility. To achieve maximum efficacy, recommendations are to take desmopressin tablet 1 hour before bedtime and 2 hours after meal: this is unrealistic in schoolaged children since there never is 3 hours between evening meal and bedtime. In 2005 a dose response study demonstrated superior pharmaco-kinetic and dynamic properties for desmopressin Lyophilisate MELT formula. Since these results implicate superior action of MELT, often a change to MELT is recommended if there is a suboptimal response with tablet: sublingual absorption would eliminate the influence of food-intake. However, for this statement there's no evidence, since these tests were all conducted in children in fasting condition. Only one clinical study demonstrates bioequivalence for MELT and tablet. Hypothesis is that desmopressin MELT formulation has a better bioavailability when administered together with meal due to its sublingual absorption.
Interventions
DRUGdesmopressin tablet
Administration of desmopressine tablet
DRUGdesmopressin MELT formulation
Administration of desmopressine MELT formulation
Sponsors
University Hospital, Ghent
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 16 Years
Healthy volunteers
No
Inclusion criteria
* children aged 6-16 years old * with MNE and nocturnal polyuria * treated with desmopressin tablet, non or partial responders, for whom change to MELT formulation is indicated according to the international standard guidelines.
Exclusion criteria
* history of urologic disease, diurnal urinary incontinence, diabetes insipidus, urinary tract infection, clinically significant disease * No systemic use of antibiotics, diuretics, other medication that influences urinary concentrating mechanism * abnormalities of oral mucosa which could influence drugrelease or absorption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bioavailability of desmopressine MELT and tablet when taken with meal. | at 1h, 2h and 6h post adminstration |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic and pharmacodynamic for desmopressine MELT and tablet. | at 1h, 2h, 3h, 6h and 8h post administration |
Countries
Belgium
Outcome results
None listed